University of Colorado Cancer Center.
Moffitt Cancer Center.
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non-muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.
本 NCCN 临床实践指南（NCCN 指南）膀胱癌部分精选内容重点介绍疑似膀胱癌的临床表现和检查、非肌肉浸润性尿路上皮膀胱癌的治疗以及转移性尿路上皮膀胱癌的治疗，因为这些部分最近有了重要更新。一些重要的更新包括在卡介苗（BCG）短缺的情况下为非肌肉浸润性膀胱癌提供最佳治疗的建议，以及关于晚期或转移性疾病生物标志物检测的详细信息。二线或后续治疗的系统治疗建议也已修订。NCCN.org 上提供的完整版本的 NCCN 膀胱癌指南涵盖了肌层浸润性、非转移性疾病的治疗和管理。完整版本中还涵盖了其他主题，包括非尿路上皮组织学的治疗和对上尿路尿路上皮癌、前列腺尿路上皮癌和尿道原发性癌等非膀胱尿路癌的建议。
